Antivaccine immune responses
| Patient (CIP) . | Immune responses . | T-cell frequency anti–MAGE-A3* . | ||||||
|---|---|---|---|---|---|---|---|---|
| Ex vivo . | In vivo (DTH) . | |||||||
| TK . | M3 . | TK . | M3 . | Pre . | Post . | |||
| CIP-5 | + | + | + | + | 3.8 × 10−7 | 3.0 × 10−5 | ||
| CIP-6 | + | − | +/− | − | NA | NA | ||
| CIP-11 | − | − | − | − | 5.2 × 10−7 | < 5.2 × 10−7 | ||
| CIP-13 | + | − | − | − | 1.6 × 10−6 | 7.9 × 10−7 | ||
| CIP-18 | +/− | − | NA | NA | ||||
| CIP-19 | + | + | 3.9 × 10−7 | 1.7 × 10−5 | ||||
| CIP-21 | + | − | − | − | 9.3 × 10−7 | < 9.3 × 10−7 | ||
| CIP-23 | + | − | − | − | 5.2 × 10−7 | 5.8 × 10−7 | ||
| CIP-25 | + | − | − | − | 9.5 × 10−7 | 5.4 × 10−7 | ||
| CIP-26 | + | + | + | + | 2.2 × 10−6 | 1.8 × 10−5 | ||
| Patient (CIP) . | Immune responses . | T-cell frequency anti–MAGE-A3* . | ||||||
|---|---|---|---|---|---|---|---|---|
| Ex vivo . | In vivo (DTH) . | |||||||
| TK . | M3 . | TK . | M3 . | Pre . | Post . | |||
| CIP-5 | + | + | + | + | 3.8 × 10−7 | 3.0 × 10−5 | ||
| CIP-6 | + | − | +/− | − | NA | NA | ||
| CIP-11 | − | − | − | − | 5.2 × 10−7 | < 5.2 × 10−7 | ||
| CIP-13 | + | − | − | − | 1.6 × 10−6 | 7.9 × 10−7 | ||
| CIP-18 | +/− | − | NA | NA | ||||
| CIP-19 | + | + | 3.9 × 10−7 | 1.7 × 10−5 | ||||
| CIP-21 | + | − | − | − | 9.3 × 10−7 | < 9.3 × 10−7 | ||
| CIP-23 | + | − | − | − | 5.2 × 10−7 | 5.8 × 10−7 | ||
| CIP-25 | + | − | − | − | 9.5 × 10−7 | 5.4 × 10−7 | ||
| CIP-26 | + | + | + | + | 2.2 × 10−6 | 1.8 × 10−5 | ||
Bold text in table body indicates responding patients.
CIP indicates cancer immunotherapy patient; M3, MAGE-3; and NA, not applicable.
The frequencies of MAGE-A3 precursors were determined by the Poisson distribution analysis as reported in “Semiquantitative assessment of TK- and MAGE-A3–specific T cells among peripheral and tumor-infiltrating lymphocytes.”